RAPID Score Validated for Prognosis of Pleural Infections

Share this content:
RAPID Score Validated for Prognosis of Pleural Infections
RAPID Score Validated for Prognosis of Pleural Infections

WEDNESDAY, July 29, 2015 (HealthDay News) -- The recently developed RAPID score, which identifies the risk of mortality in patients with pleural infections based on five clinical factors, has been validated in a diverse patient cohort. The findings have been published online July 20 in the Annals of the American Thoracic Society.

Heath D. White, D.O., from Baylor Scott & White Health in Temple, Texas, and colleagues aimed to further validate the RAPID score in a diverse cohort including 187 patients with culture-positive pleural infections. Patients were classified into low-, medium-, and high-risk groups based on RAPID scores (0 to 2, 3 to 4, and 5 to 7, respectively). The researchers examined all-cause mortality at three months and at one, three, and five years.

The researchers found that the three-month mortality scores were 1.5, 17.8, and 47.8 percent, respectively, for low-, medium-, and high-risk groups, with increased odds for the medium- and high-risk groups (odds ratios, 14.3 and 53.3, respectively). At one, three, and five years, the trend continued. Gram-negative rod infections, heart disease, diabetes, cancer, lung disease, and increased length of stay correlated with high risk scores.

"When applied to a diverse patient cohort, the RAPID score predicts outcomes in patients up to five years and may aid in long term risk stratification on presentation," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »